Business
Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting
SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene
About this update from Clene Inc.
[{"type":"text","content":"SALT LAKE CITY, April 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced three presentations at the upcoming 2023 American Academy of Neurology (AAN) Annual Meeting, taking place April 22-27, 2023, in Boston, MA. The platform presentations and poster highlight the results from three clinical trials that demonstrated clinical benefit and safety of treatment with CNM-Au8®. Details of the three presentations are as follows: Title: VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple SclerosisPlatform Session: PL5, Clinical Trials Plenary SessionPresenter: Michael Barnett, Ph.D.Date & Time: Tuesday, April 25, 9:15 AM - 11:30 AM EST Title: Results from the first four regimens of the HEALEY ALS Platform TrialPlatform Session: PL5, Clinical Trials Plenary SessionPresenter: Sabrina Paganoni, MD, Ph.D.Date & Time: Tuesday, April 25, 9:15 AM - 11:30 AM EST Title: Evidence for Survival Benefit in ALS with CNM-Au8 Treatment Across Three Study PopulationsPoster Session: P8, Neuromuscular Disease: Amyotrophic Lateral Sclerosis 1 Presenter: James Berry, MD, MPHDate & Time: Tuesday, April 25, 11:45 AM - 12:45 PM EST The posters will be available in the Presentations section of the Clene website on April 25. section of the Clene website on April 25. About CNM-Au8®CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization. The catalytically active nanocrystals of CNM-Au8 drive critical cellular energy producing reactions that enable neuroprotection and remyelination by increasing neuronal and glial resilience to disease-relevant stressors. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. About CleneClene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake Ci...